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activity, adiponectin or omentin-1 and hormone use was 
used to investigate potential relationships between the adi-
pokines and BUA levels. A mediation analysis assessed the 
mediating effect of OPG on the association of BUA and 
omentin-1 levels.
Results Peri-/premenopausal women had higher BUA lev-
els (112.5 ± 10.1 dB/MHz), compared to postmenopausal 
women (106.3 ± 10.0 dB/MHz). In peri-/premenopausal 
women neither adiponectin nor omentin-1 was significantly 
associated with BUA. In postmenopausal women, adi-
ponectin was not associated with BUA, but 10 % increase 
in the omentin-1 concentration was significantly associated 
with 0.44 dB/MHz lower BUA levels (p = 0.01). Omen-
tin-1 was positively associated with OPG (p = 0.02); how-
ever, OPG was not significantly related to BUA (p = 0.62).
Conclusion Our study provides evidence for an inverse 
association between circulating omentin-1 and BUA levels 
in postmenopausal women. However, the present findings 
Abstract 
Purpose Several studies implicated a crosstalk between 
bone and fat in the pathogenesis of osteoporosis. Few stud-
ies indicated an association between adiponectin and omen-
tin-1 on the bone remodeling process and bone mineral 
density, and suggested osteoprotegerin (OPG) as a mediator 
of this relationship. However, only limited evidence on this 
relationship is available in humans. Therefore, this study 
aimed to investigate the association between omentin-1, 
adiponectin and broadband ultrasound attenuation (BUA) 
in peri-/premenopausal and postmenopausal women, and to 
assess the role of OPG as a possible mediator.
Methods Data from the German population-based EPIC-
Potsdam cohort comprising 637 women were analyzed. 
Multivariable-adjusted ANCOVA including age, BMI, 
waist circumference, smoking status, education, physical 
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do not support a mediating effect of OPG in the adipose tis-
sue–bone pathway.
Keywords Intelectin-1 · Osteoclastogenesis inhibitory 
factor · Bone mineral density · Broadband ultrasound 
attenuation
Introduction
Osteoporosis is a systemic skeletal disease characterized 
by reduced bone mass and micro-architectural deterioration 
of bone tissue with a consequent increase in bone fragil-
ity, susceptibility to fractures and reduced quality of life 
[1]. In women, an accelerated loss of bone mineral density 
(BMD) occurs after menopause. Many factors, including 
low BMI [2], decreased physical activity [3] and smok-
ing [4], contribute to this bone loss. Recently, it has been 
suggested that adipocyte-dependent hormonal factors may 
play an important role in bone health [5, 6]. In particular, 
omentin-1 and adiponectin may act as novel determinants 
of BMD.
Adiponectin is an adipocyte-secreted adipokine 
inversely related to adiposity. Adiponectin has been sug-
gested to exert anti-inflammatory, antiatherogenic, and 
insulin-sensitizing effects [7]. Notably, adiponectin and its 
receptors have been found to be produced by human bone-
forming cells, suggesting that adiponectin may link adi-
pose tissue to BMD [8]. A recent meta-analysis noticed an 
inverse association between adiponectin and BMD [9]. The 
association between adiponectin and the remodeling pro-
cess, i.e., the removal of mineralized bones by osteoclasts 
followed by the formation of new bone through the osteo-
blasts, has also been studied in experimental in vitro and 
in vivo studies [10], however, showing conflicting results 
of adiponectin on bone metabolism. On the one hand, adi-
ponectin was suggested to induce osteoblast proliferation 
and differentiation [11, 12]. On the other hand, it has been 
demonstrated that adiponectin promotes increased osteo-
clast formation indirectly by stimulating receptor activator 
for nuclear factor κB ligand (RANKL) and by inhibition 
of osteoprotegerin (OPG) production [13, 14]. OPG and 
RANKL are both secreted by osteoblasts. OPG belongs to 
the TNF-receptor superfamily and is part of a newly deline-
ated cytokine system, and acts as a decoy receptor, bind-
ing to RANKL, preventing the activation of precursor cells, 
and ultimately inhibiting bone resorption [15]. RANKL, 
binds its receptor (RANK) settled on osteoclast precursor, 
thus leading to osteoclast differentiation [15]. Thus a sys-
temic effect of adiponectin on BMD remains unclear.
Omentin-1 was discovered from a human omental fat 
cDNA library and is mainly expressed in visceral adipose 
tissue [16]. Recent studies have shown that omentin-1 is 
inversely related to BMI and waist circumference [17]. 
Moreover, positive associations with adiponectin and high 
density lipoprotein cholesterol were reported [17].
To date, only a few cross-sectional studies investigated 
the association between circulating omentin-1 and BMD 
in apparently healthy people showing inconsistent results 
[18–21]. In an experimental study high omentin-1 concen-
trations restored BMD, via RANKL inhibition and stimula-
tion of OPG [22].
The present study aimed to investigate the relationship 
between omentin-1, adiponectin and broadband ultrasound 
attenuation (BUA), as one parameter reflecting bone health, 
in peri-/premenopausal and postmenopausal women, 
respectively. Furthermore, we examined whether the asso-
ciation between omentin-1 and BUA or adiponectin and 
BUA was mediated by OPG.
Methods
Study population
The European Prospective Investigation into Cancer and 
Nutrition (EPIC)-Potsdam Study is a prospective cohort 
study. Between 1994 and 1998, 10,904 men and 16,644 
women aged 35–64 years were recruited from the general 
population of Potsdam and surrounding communities [23]. 
The recruitment process was based on residents’ registra-
tion offices [23]. In women (n = 9711), from 1996 until the 
end of the recruitment phase, quantitative ultrasound meas-
urements (QUS) were part of the baseline examination.
Omentin-1, adiponectin and OPG concentrations were 
measured in a random subsample of 929 out of the 9711 
women with already measured BUA levels. For the present 
study, we excluded 12 participants due to age at baseline 
below 35 years, 232 due to undefined menopausal status, 
i.e., no clear classification of women to “peri-/premenopau-
sal”, “postmenopausal” or “surgical menopausal” status. 
Moreover, we excluded women with surgical menopause 
(n = 38), postmenopausal women taking oral contracep-
tives (n = 2) or with missing covariates data (n = 8). The 
final study population consisted of 637 women (388 peri-/
premenopausal and 249 postmenopausal).
Quantitative ultrasound measurement
QUS were performed by trained personnel on the right 
os calcis using Achilles Plus Ultrasound Densitometer 
(Lunar Corporation, Madison, WI 53713, USA) according 
to manufacturer instructions. BUA was measured in deci-
bel/megahertz (dB/MHz), predefined as the slope of the 
signal attenuation versus the frequency curve in the usu-
ally measured range of 0.1–1 MHz [24]. In a sub-study, 
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11 women were measured 10 times within 3 weeks and a 
within-person variation coefficient of 1.47 % of BUA was 
observed [25].
Blood collection and laboratory analysis
A total of 30 ml of venous blood was collected at baseline 
from participants at the Potsdam study center. Levels of 
adiponectin, omentin-1 and OPG were determined in cit-
rate plasma. Biomarker concentrations were multiplied by 
1.16 in order to obtain levels for citrate plasma samples 
comparable to levels obtainable from EDTA plasma [26]. 
Adiponectin was quantified at the Department of Internal 
Medicine, University of Tübingen, with an enzyme-linked 
immunosorbent assay from Linco Research, St Charles, 
Missouri, with intra-assay and inter-assay coefficients of 
variation (CVs) between, 0.1–6.2 and 5.0 %, respectively. 
Plasma concentrations of omentin-1 and OPG were meas-
ured at the Institute of Clinical Chemistry, University 
Magdeburg. Omentin-1 was determined by a sandwich 
ELISA (Biovendor, Brno, Czech Republic) with intra-assay 
CVs between 3.2 and 4.1 %, inter-assay CVs between 4.4 
and 4.8 % and a limit of detection of 0.5 ng/ml, accord-
ing to manufacturer. We previously reported excellent 
reliability of single measurements of omentin-1 indicated 
by an intraclass correlation coefficient of 0.83 (95 %-CI 
0.78–0.87) [27]. OPG concentrations were quantified at the 
Institute of Clinical Chemistry, University of Magdeburg, 
using a sandwich ELISA (Biovendor, Brno, Czech Repub-
lic) with intra-assay CVs between 2.9 and 4.9 % and inter-
assay CVs between 1.7 and 9.0 % and limit of detection of 
0.03 pmol/l.
Assessment of lifestyle characteristic, dietary intake 
and other covariates
At baseline, self-administered questionnaires on nutrition 
and lifestyle were filled out and computer-based inter-
views on lifestyle and medical histories were conducted 
[28]. Calibrated baseline EPIC-Germany physical activity 
data was used. Briefly, the physical activity levels calcula-
tion was based on a comprehensive physical activity ques-
tionnaire and objectively measured acceleration counts [3, 
29]. Trained and quality personnel took the anthropomet-
ric measurements with participants wearing light under-
wear and no shoes, weight was measured with electronic 
digital scales, accurate to 100 g (Soehnle, type 7720/23, 
Murrhardt, Germany) and the height to the nearest 0.1 cm 
by using a flexible anthropometer. BMI was calculated as 
body weight (kg) divided by squared height (m2). Meno-
pausal status was assessed according to self-reported infor-
mation about menstrual status and history. Self-reported 
medication over the past 4 weeks prior to study enrolment 
was used to identify users of oral contraceptive, hormone 
replacement therapy (HRT).
Statistical analysis
All analyses were performed separately for peri-/premeno-
pausal (n = 388) and postmenopausal (n = 249) women. 
Normally distributed variables were reported as mean and 
standard derivation. Right skewed variables (omentin-1, 
adiponectin, osteoprotegerin) were reported as median and 
interquartile range, and log transformed for the analyses. 
Categorical variables were reported as percentage (smok-
ing status, educational level, oral contraceptive and HRT 
use). For comparison of the characteristics between peri-/
premenopausal women and postmenopausal women a Chi-
square test for categorical variables and a Student’s t test 
or Mann–Whitney U test for continuous variables was 
used. Correlations between adipokines, BUA and OPG 
were assessed using Spearman age-adjusted partial corre-
lation coefficients. Multivariable linear regression models 
were used to estimate the associations between the adi-
pokines, adiponectin and omentin-1, with BUA, adjusted 
for age (continuous), BMI (continuous), waist circum-
ference (continuous), smoking status (non-smoker, ex-
Smoker <5 years, ex-Smoker ≥5 years, smoker <20 ciga-
rettes/day, smoker ≥20 cigarettes/day), educational level 
(unskilled or skilled, technical college, university degree), 
physical activity (continuous), use of oral contraceptive 
(yes/no) and HRT (yes/no), respectively, for peri-/pre-
menopausal and postmenopausal women. The models were 
additionally mutually adjusted for each adipokine (log-
transformed omentin-1 or log-transformed adiponectin). 
Multivariable-adjusted analysis of covariance (ANCOVA) 
was used to assess the relationship between omentin-1 and 
BUA according to menopausal status-specific quartiles of 
omentin-1. Same analysis was performed according meno-
pausal status-specific quartiles of adiponectin. To examine 
whether the association between omentin-1 and BUA was 
mediated by OPG, three fully adjusted linear regressions 
models were fitted based on the conventional steps outlined 
by Baron and Kenny [30]. The first model investigated the 
association between the mediator and the independent vari-
able (path a). The second model determined the association 
between the dependent variable and independent variable 
(path c). The third model examined the association between 
the dependent variable and both independent variable and 
mediator included in the final model (path b and c’) [30]. 
The mediation model decomposes the total effect of inde-
pendent variable on dependent variable (path c), into two 
parts: the indirect effect of independent variable on depend-
ent variable via mediator, quantified by the product of the 
β-coefficients of path a and path b, and the direct effect of 
independent variable on dependent variable with the effect 
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of the possible mediator removed, quantified by the path c′ 
(c = ab + c′) [31]. A bootstrapping analysis (1000 boot-
strap samples, sampling rate 80 %) was used to estimate 
the mean size (95 %-CI) of total, direct and indirect effect, 
and further to test the statistical significance of the indirect 
effect [32]. The variance accounted for (VAF) determines 
the size of the indirect effect in relation to the total effect 
(VAF > 80 %: full mediation; 80 % > VAF > 20 %: partial 
mediation; VAF < 20 %: no mediation) [33]. A sensitivity 
analysis, performed in 243 participants noticed no changes 
in results with additionally adjustment of vitamin D, estra-
diol and sex hormone binding globulin (data not shown). A 
p value <0.05 was considered to be statistically significant. 
All statistical analyses were performed using SAS soft-
ware, version 9.4 (SAS institute, Cary, N.C., USA).
Results
Table 1 shows the basic characteristics of the 637 women, 
stratified by menopausal status. Compared to post-
menopausal women (n = 249), peri-/premenopausal 
women (n = 388) were younger (p < 0.0001), had higher 
BUA (p < 0.0001), lower omentin-1 (p < 0.0001), OPG 
(p < 0.0001) and adiponectin levels (p = 0.0002).
We noticed no relevant correlations between adiponectin 
and BUA or OPG in peri-/premenopausal women as well 
as in postmenopausal women (Online Resource 1). In line, 
multivariable-adjusted linear regression models detected no 
associations between adiponectin and BUA (Table 2), as 
well as between adiponectin and OPG levels in both peri-/
premenopausal or postmenopausal women.
We observed no association between omentin-1 and 
BUA in peri-/premenopausal women (Table 2). However, in 
postmenopausal women, omentin-1 was inversely related to 
BUA levels even after adjustment for age, BMI, waist cir-
cumference, smoking status, educational attainment, use of 
HRT and log-transformed adiponectin levels. In particular, 
a 10 % increase in omentin-1 levels was significantly asso-
ciated with 0.44 dB/MHz lower BUA (p = 0.01) (107.0 
95 %-CI 103.8–110.2 dB/MHz versus 103.0 95 %-CI 99.6–
106.4 dB/MHz for the highest versus the lowest quartile of 
omentin-1; Table 2).
Therefore, we tested the mediating effect of OPG on the 
association between BUA and omentin-1 levels in postmen-
opausal women only. As shown in Fig. 1, a 10 % increase 
in omentin-1 was associated with 1.0 % higher OPG levels 
(p = 0.02), whereas omentin-1 was negatively associated 
with BUA levels. When omentin-1 and OPG were simul-
taneously included in the fully adjusted model, OPG was 
not significantly associated with BUA levels (p = 0.62) 
(Fig. 1). Bootstrapping analysis showed a statistically 
significant indirect effect of omentin-1 on BUA via OPG 
(β-coefficient mean bootstrap 0.13, 95 %-CI bootstrap 
Table 1  Characteristics of the 
study population according 
to menopausal status (EPIC-
Potsdam Study, women, 
n = 637)
Variables are expressed as percentage, or mean ± standard deviation, or median (interquartile range)
Peri-/premenopausal 
women (n = 388)
Postmenopausal  
women (n = 249)
p value
BUA (dB/MHz) 112.5 ± 10.1 106.3 ± 10.0 <0.0001
Age (years) 41.2 ± 4.6 59.0 ± 3.6 <0.0001
BMI (kg/m2) 24.3 ± 4.5 27.3 ± 4.8 <0.0001
Waist circumference (cm) 77.2 ± 11.4 85.2 ± 11.3 <0.0001
Physical activity (counts/min/day) 41.0 ± 5.2 32.0 ± 5.1 <0.0001
Smoking status (%) <0.0001
 Non-smoker 44.3 64.3
 Ex-smoker <5 years 20.9 17.7
 Ex-smoker ≥5 years 9.5 5.6
 Smoker <20 cigarettes/day 20.6 10.4
 Smoker ≥20 cigarettes/day 4.9 2.0
Educational level (%) <0.0001
 Unskilled or skilled 31.2 42.6
 Technical college 26.0 36.1
 University degree 42.8 21.3
Oral contraceptive intake (%) 34.5 – <0.0001
Hormone replacement therapy (%) – 24.1 <0.0001
Adiponectin (µg/ml) 8.7 (6.6–12.0) 10.4 (7.6–13.6) 0.0002
Omentin-1 (ng/ml) 368.3 (303.3–439.1) 452.4 (374.7–546.7) <0.0001
Osteoprotegerin (pmol/l) 4.3 (3.6–5.3) 5.1 (4.3–5.7) <0.0001
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0.12-0.14; Table 3). However, the VAF in mediation model 
was 3 %, suggesting lack of mediation effect of OPG on the 
association between omentin-1 and BUA levels (Table 3).
Discussion
In the present study we investigated the relationships 
between the adipokines, adiponectin and omentin-1, and 
BUA and examined the role of OPG as a possible media-
tor in these associations in peri-/pre- and postmenopausal 
women. Adiponectin was not related to BUA levels in both 
peri-/pre- and postmenopausal women; whereas omentin-1 
was significantly negatively related to BUA levels in post-
menopausal women only. Contrary to our hypothesis, this 
association was not mediated by OPG levels.
Results from a meta-analysis of observational studies 
suggest an inverse relationship between adiponectin and 
BMD, with five studies showing a negative association and 
five others showing no association [9]. However, in line 
with our findings, also other studies failed to observe an 
association between adiponectin and BMD levels [34–37].
Accordingly, results from in vitro and in vivo studies 
have shown conflicting results. On the one hand, adiponec-
tin was suggested to induce osteoclast formation via stimu-
lation of RANKL and inhibition of OPG production [13, 
Table 2  Quartiles of omentin-1 and adiponectin with adjusted BUA values according to menopausal status
Adjusted for age, waist circumference, BMI, smoking status, education, physical activity
a Additionally adjusted for adiponectin (log transformed)
b Additionally adjusted for oral contraceptive use
c Additionally adjusted for omentin-1 (log transformed)
d Additionally adjusted for hormone replacement therapy
n Omentin-1 (ng/ml) BUA (dB/MHz)a,b p for trend
Median (IQR) Adjusted mean (95 %-CI)
Peri-/premenopausal women (n = 388)
 Q1 97 256.4 (230.8, 285.4) 111.0 CI (108.8, 113.2) 0.4
 Q2 97 334.1 (321.3, 350.3) 111.0 CI (108.8, 113.2)
 Q3 97 395.6 (384.0, 419.9) 112.9 CI (110.6, 115.2)
 Q4 97 494.2 (460.5, 568.4) 111.7 CI (109.4, 114.1)
n Omentin-1 (ng/ml) BUA (dB/MHz)a,d p for trend
Median (IQR) Adjusted mean (95 %-CI)
Postmenopausal women (n = 249)
 Q1 62 322.9 (284.2, 342.2) 107.0 CI (103.8, 110.2) 0.02
 Q2 63 417.6 (394.4, 436.2) 106.9 CI (103.7, 110.2)
 Q3 62 495.9 (472.1, 520.8) 106.2 CI (103.2, 109.2)
 Q4 62 614.2 (590.4, 692.5) 103.0 CI (99.6, 106.4)
n Adiponectin (µg/ml) BUA (dB/MHz)b,c p for trend
Median (IQR) Adjusted mean (95 %-CI)
Peri-/premenopausal women (n = 388)
 Q1 97 5.42 (4.46, 5.93) 110.6 CI (108.3, 112.9) 0.9
 Q2 97 7.82 (7.17, 8.29) 112.9 CI (110.7, 115.0)
 Q3 97 10.30 (9.48, 11.10) 112.5 CI (110.2, 114.7)
 Q4 97 14.31 (13.07, 15.90) 110.5 CI (108.2, 112.8)
n Adiponectin (µg/ml) BUA (dB/MHz)c,d p for trend
Median (IQR) Adjusted mean (95 %-CI)
Postmenopausal women (n = 249)
 Q1 62 5.56 (5.04, 6.67) 106.8 CI (103.6, 110.0) 0.3
 Q2 62 9.14 (8.44, 9.70) 106.0 CI (102.7, 109.3)
 Q3 63 11.65 (10.98, 12.41) 106.9 CI (103.7, 110.1)
 Q4 62 16.37 (14.29, 17.82) 104.2 CI (101.0, 107.5)
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14]; on the other hand, adiponectin was shown to induce 
osteoblast proliferation and differentiation [12], and to 
increase bone mass via osteoclastogenesis suppression and 
osteoblastogenesis activation [11]. Yet, the reason for such 
discrepant findings is unclear, but it is conceivable that iso-
lated cell culture models and animal models are limited in 
their capability to emulate complex processes, like possi-
ble adiponectin-dependent counter-regulatory mechanisms. 
Therefore, the biological action of adiponectin in bone 
biology still needs to be elucidated.
To date, only a few studies investigated the relation-
ship between the novel adipokine omentin-1 and BMD in 
apparently healthy people. As shown by Li et al. omentin-1 
was negatively correlated with BMD of the total body and 
lumbar spine in Chinese men; however, this correlation lost 
statistical significance after adjustment of age, BMI and 
fat body mass [20]. Moreover, a negative correlation was 
found between omentin-1 and BMD at femoral neck, total 
hip and ward’s triangle, albeit not statistically significant. 
In line with our results in postmenopausal women Tohidi 
et al. observed a significant inverse association between 
omentin-1 and BMD [19] and the study of Zhang et al. sup-
ports this inverse association, though this association was 
not statistically significant [21]. In contrast, Wang et al. [18] 
observed an inverse relationship between omentin-1 and 
BMD in premenopausal, but not in postmenopausal women.
In vitro and in vivo studies suggest that omentin-1 may 
play a protective role in both bone remodeling process 
and BMD. In co-culture systems of osteoblast and osteo-
clast precursors, omentin-1 was shown to reduce osteoclast 
formation via OPG and to inhibit RANKL production in 
osteoblasts [22]. Second, omentin-1 treatment significantly 
enhanced BMD in ovariectomized mice (a widely used 
mice model for postmenopausal women [38]) accompa-
nied by higher serum OPG and lower RANKL levels, sug-
gesting a bone-sparing effect of omentin-1 via OPG and 
RANKL [22].
The current study supports a positive association 
between omentin-1 and OPG in postmenopausal women, 
in line with Xie and colleagues findings [22]. However, 
we observed no association between OPG and BUA levels, 
which questions a mediating effect of OPG in the adipose 
tissue–bone crosstalk. Nonetheless, experimental studies 
indicate an OPG-dependent bone remodeling mechanism, 
whereas human studies have provided controversial results 
regarding the relationship of OPG on bone remodeling 
marker and BMD [39–42]. The reason for this controversy 
might be explained by the fact that rather than OPG, the 
OPG/RANKL ratio most likely influences the static meas-
ure of BMD [43], thus maintaining an appropriate balance 
of bone remodeling. Therefore, further studies are required 
to explore RANKL and OPG/RANKL ratio as potential 
mediators in the adipose tissue–bone association.
Fig. 1  OPG (log transformed) mediation model of the relationship 
between omentin-1 (log transformed) and BUA in postmenopausal 
women (n = 249). Mediation model decomposes the total effect of 
omentin-1 on BUA (path c), into indirect effect of omentin-1 on BUA 
via mediator OPG, quantified by the product of the β-coefficients of 
path a and path b, and the direct effect of omentin-1 on BUA, when 
the effect of the possible mediator was removed, quantified by the 
path c′; adjusted for age, BMI, waist circumference, physical activity, 
smoking, education, hormone replacement therapy, log-transformed 
adiponectin; BUA: broadband ultrasound attenuation, OPG osteopro-
tegerin, SE standard error
Table 3  Decomposition of the total effect of omentin-1 (log trans-
formed) on BUA in postmenopausal women (n = 249) into an indi-
rect effect mediated by OPG (log transformed) and a non-mediated 
direct effect
Mean and 95 %-CI were estimated by bootstrapping analysis (1000 
bootstrap samples, sampling rate 80 %)
VAF variance accounted for mediation
Mean bootstrap 95 %-CI  
bootstrap
Total effect (β-coefficient) −4.63 −4.69 to −4.57
Direct effect (β-coefficient) −4.76 −4.82 to −4.70
Indirect effect (β-coefficient) 0.13 0.12 to 0.14
VAF (%) 3.00 2.77 to 3.23
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Overall, the higher omentin-1 and lower BUA levels 
observed in postmenopausal women might be due to a 
physiological compensation and adaptation to bone loss. 
Even if we observed an inverse association between omen-
tin-1 and BUA levels, it cannot be ruled out that omentin-1 
may attenuate the stronger bone removal in these women. 
However, the cross-sectional design of the present study 
does not allow for causal inference, therefore we cannot 
clarify whether the observed omentin-1 concentrations are 
pathological or compensatory. Furthermore, because the 
present study comprises middle-aged Caucasian women, 
these findings may not be generalizable to other ethnic or 
age groups.
Additional limitations of the present study deserve to be 
mentioned. First, BUA, derived from QUS measurements 
on the right os calcis only, was used as a proxy of BMD 
measures, commonly measured with dual energy X-ray 
absorptiometry technique. Yet, BUA has been validated sat-
isfactorily several times against BMD [44], thus represent-
ing a non-invasive valid, inexpensive, easy, and quick alter-
native measure for BMD. Furthermore, the present findings 
are based on one single baseline measurements of omen-
tin-1 and adiponectin levels. However, we observed excel-
lent reliability of omentin-1 measurements within individu-
als over time [27]. Adiponectin level have also been shown 
to be stable over time [45].
Strengths of our study include the population-based 
sample with suitable comparison between peri-/premeno-
pausal and postmenopausal women, and the availability of 
high-quality data as a result of the standardized procedures 
enabling us to adjust for the most important potential con-
founders. However, other important factors that may influ-
ence the relation between adipokines and BUA such as 
vitamin D or sexual hormones have not been measured in 
all participants of the study population.
In conclusion, this study shows no association between 
adiponectin and BUA levels. However, higher plasma 
omentin-1 levels were associated with lower BUA levels 
in postmenopausal women. We did not find evidence of a 
mediating effect of OPG in the association between omen-
tin-1 and BUA levels.
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